David Livermore profile photo

David Livermore

Professor of Medical Microbiology

Norwich, UNITED KINGDOM

His work focuses on rapid & more precise detection of antibiotic resistance in order to identify the most appropriate antibiotic treatments.

Media

Publications

Documents

Photos

Audio

Video

Image for youtube videos on BSAC Spring Conference 2018 - Day2 - Professor David Livermore

Biography

David Livermore is Professor of Medical Microbiology in the Norwich Medical School at UEA. He is an expert on antibiotic resistance. His work focuses on rapid and more precise detection of antibiotic resistance in order to identify the most appropriate antibiotic treatments. He conducts trials for new diagnostics of antibiotic resistance. He also acts as a consultant to the pharmaceuticals industry, assessing new antibiotics against multi-resistant bacteria. Current interests include: the potential for secondary bacterial pneumonias in COVID-19 patients, investigation of Colistin as an antibiotic (used as a last-resort for multidrug-resistant infections including pneumonia) to treat Enterobacter infections, and rapid diagnostics for hospital patients with ventilator-associated pneumonia.

David previously lead the National Antibiotic Resistance Laboratory for Public Health England for 14 years and he worked at the London Hospital Medical College on mechanisms of resistance to antibiotics in bacteria. He sits on the British Society for Antimicrobial Chemotherapy’s working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and its Antibiotic Action advisory board. He is also on the Society for General Microbiology working group on sexually transmitted infections. He is also a member of the UK Government’s Antimicrobial Resistance and Healthcare Associated Infections Advisory Committee. He has edited several journals including Journal of Antimicrobial Chemotherapy and Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.

Areas of Expertise

Antimicrobial AgentsBacteriaMicrobiologyAntibiotic ResistanceEnterobacter Infections

Education

University of London

Ph.D., Medical Microbiology

1983

Heriot-Watt University

B.Sc., Microbiology

1978

Affiliations

  • DoH Antimicrobial Resistance Diagnostics Sub-Group: 2015 to present
  • PHE Gonococcal Resistance to Antibiotics Surveillance Programme; Steer Group Chairman: 2014 to present
  • Editorial Board, Korean Journal of Internal Medicine: 2011 to present
  • International Advisory Board, Journal of Microbiology, Immunology & Infection: 2010 to present
  • Editorial Board, Antimicrobial Agents and Chemotherapy: 1996 to present

Media Appearances

Norwich researchers play part in pneumonia test for coronavirus patients

Eastern Daily Press  online

2020-04-25

The study’s co-chief investigator, Prof David Livermore from UEA’s Norwich Medical School, said: “We know that some Covid-19 patients get secondary pneumonias but it’s a new disease and no one knows what types of bacteria are most likely.

view more

Study: Not washing your hands after bathroom more harmful than eating raw meat

Atlanta Journal Constitution  online

2019-10-25

"The great majority of strains of ESBL-E. coli causing human infections aren't coming from eating chicken, or anything else in the food chain," lead author David Livermore said in a statement. "The likeliest route of transmission for ESBL-E. coli is directly from human to human, with fecal particles from one person reaching the mouth of another.

view more

Washing your hands is the best way to stop the E. coli superbug

CNN  online

2019-10-23

"Infections caused by ESBL-E. coli bacteria are difficult to treat. And they are becoming more common in both the community and hospitals," David Livermore of the University of East Anglia's Norwich Medical School said. Livermore said mortality rates among people infected with these superbug strains are double those of people infected with strains that are susceptible to treatment.

view more

Washing your hands is the best way to stop the E. coli superbug

CTV News  online

2019-10-23

"Infections caused by ESBL-E. coli bacteria are difficult to treat. And they are becoming more common in both the community and hospitals," David Livermore of the University of East Anglia's Norwich Medical School said.

view more

Poor toilet hygiene more likely to spread E.coli than food, scientists say

Express & Star  online

2019-10-22

Professor David Livermore, from the University of East Anglia’s Norwich Medical School, who is the study’s main author, said: “The great majority of strains of ESBL-E.coli causing human infections aren’t coming from eating chicken, or anything else in the food chain.

view more

Articles

In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria | American Society for Microbiology

2020

Cefiderocol is a parenteral siderophore cephalosporin, with a catechol-containing 3′ substituent. We evaluated its MICs against gram-negative bacteria, using iron-depleted Mueller-Hinton broth. The panel comprised 305 Enterobacterales, 111 P. aeruginosa and 99 A. baumannii, all selected for carbapenem resistance and multi-resistance to other agents.

view more
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data | Journal of Antimicrobial Chemotherapy

2020

Ceftaroline and ceftobiprole inhibit most MRSA and MDR pneumococci. Few direct comparisons of their activity have been published, but in several years (2008, 2013, 2017 and 2018) both were tested in parallel in the BSAC Resistance Surveillance Programme, giving paired results. These are reviewed.

view more
Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline | American Society for Microbiology

2020

Modern medicine is threatened by the global rise of antibiotic resistance, especially among Gram-negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are increasingly disseminated worldwide, though particularly in Asia. Many MBL producers have multiple further drug resistances, leaving few obvious treatment options.

view more
Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: | Clinical Infectious Diseases

2020

Carbapenem resistance in Gram-negative bacteria is a public health concern. Consequently, numerous government and agency reports discuss carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant organisms (CROs). Unfortunately, these terms are fuzzy.

view more
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy | Open Forum Infectious Diseases

2020

We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ESBL.

view more

powered byPowered By